A leading global pharmaceutical manufacturer Hetero Group emerged the first company in the world to be accorded the World Health Organisation’s (WHO) prequalification of medicines programme (WHO-PQ) for its generic version of Covid-19 oral antiviral treatment candidate Nirmatrelvir. This antiviral with Ritonavir is used as part of Pfizer’s Paxlovid. The company said it, “will be rolling out its generic combi-pack under the NIRMACOM brand that will contain 150mg tablets of Nirmatrelvir and 100mg tablets of Ritonavir.” The WHO deemed the drug, Nirmatrelvir, the best option for high risk patients. “This…
Read MoreHetero bags first world WHO prequalification of medicines programme generic version of Pfizer’s Covid-19 oral drug
